|
|||||
|
|
Mucosal Healing and Long-term Outcomes of Patients With Inflammatory Bowel Diseases Receiving Clinic-Based vs Trough Concentration-Based Dosing of Infliximab |
|
| Authors: | Lieven Pouillon Marc Ferrante Gert Van Assche Paul Rutgeerts Maja Noman João Sabino Niels Vande Casteele Ann Gils Séverine Vermeire |
| Affiliation: | 1. Department of Gastroenterology and Hepatology, University Hospitals Leuven, Leuven, Belgium;3. Department of Pharmaceutical and Pharmacological Sciences, Laboratory for Therapeutic and Diagnostic Antibodies, KU Leuven, Leuven, Belgium;4. Department of Medicine, University of California San Diego, La Jolla, California |
| Abstract: | |
| Keywords: | Endoscopic TNF Antagonist Therapeutic Drug Monitoring Optimization ATI antibody to infliximab CD Crohn’s disease IBD inflammatory bowel disease IQR interquartile range TAXIT Trough Concentration Adapted Infliximab Treatment TDM therapeutic drug monitoring TNF tumor necrosis factor UC ulcerative colitis |
| 本文献已被 ScienceDirect 等数据库收录！ | |